



## Current Agreements

### **Dealdoc**

### **Development and licensing agreement for Brivaness**

Cardiome Pharma  
Eddingpharm

Dec 19 2014

## Development and licensing agreement for Brivaness

<b>Companies:</b>	<a href="#">Cardiome Pharma</a> <a href="#">Eddingpharm</a>
<b>Announcement date:</b>	Dec 19 2014
<b>Amendment date:</b>	Jul 24 2015
<b>Deal value, US\$m:</b>	4 : sum of upfront and milestone payments

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

### Details

<b>Announcement date:</b>	Dec 19 2014
<b>Amendment date:</b>	Jul 24 2015
<b>Industry sectors:</b>	Pharmaceutical
<b>Brand name:</b>	Brivaness
<b>Compound name:</b>	Vernakalant hydrochloride
<b>Asset type:</b>	Product
<b>Therapy areas:</b>	Cardiovascular » Arrhythmia
<b>Technology types:</b>	Small molecules
<b>Deal components:</b>	Development Licensing
<b>Stages of development:</b>	Phase I Asia » China Asia » Hong Kong Asia » Macau Asia » Taiwan
<b>Geographic focus:</b>	

### Financials

<b>Deal value, US\$m:</b>	4 : sum of upfront and milestone payments
<b>Upfront, US\$m:</b>	1 : upfront payment
<b>Milestones, US\$m:</b>	3 : regulatory milestone payments

### Termsheet

24 July 2015

Cardiome Pharma announced that Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China.

The study will be conducted in healthy volunteers.

Other details of the study were not disclosed.

If BRINAVESS successfully completes Phase 1, Eddingpharm anticipates initiating a pivotal Phase 3 study by year end.

---

19 December 2014

Cardiome Pharma has entered into an agreement with Eddingpharm to develop and commercialize BRINAVESS in China, Taiwan, and Macau and re-launch BRINAVESS in Hong Kong.

Eddingpharm will be responsible for any clinical trials and regulatory approvals required to commercialize BRINAVESS in the countries covered by the agreement.

Eddingpharm has agreed to an upfront payment of US \$1.0 million and specific annual commercial goals for BRINAVESS.

Cardiome is also eligible to receive regulatory milestone payments of up to US \$3.0 million.

Other financial details have not been disclosed.

## Press Release

24 July 2015

Cardiome Pharma Corp. (COM.TO) Partner Eddingpharm (Cayman) Inc. To Initiate BRINAVESS Phase I Study In China

VANCOUVER, July 24, 2015 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers. Other details of the study were not disclosed. If BRINAVESS successfully completes Phase 1, Eddingpharm anticipates initiating a pivotal Phase 3 study by year end.

"We are pleased that Eddingpharm is taking the first steps necessary to gain approval of BRINAVESS in China", said William Hunter, M.D., CEO and Director of Cardiome. "The Chinese market is an important growth driver for BRINAVESS given the region's size and demand for innovative medicines, and Eddingpharm is the perfect partner for Cardiome. Cardiome remains committed to have BRINAVESS available for all patients suffering from atrial fibrillation worldwide."

Cardiome and Eddingpharm entered into a BRINAVESS development and commercialization agreement in China, Taiwan, Macau and Hong Kong on December 19, 2014. Under the terms of the agreement, Eddingpharm made an upfront payment of US \$1.0M to Cardiome and agreed to specific annual commercial goals for BRINAVESS. Cardiome is also eligible to receive regulatory milestone payments of up to US \$3.0M. Other financial details have not been disclosed.

About Cardiome Pharma Corp. Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner AOP Orphan Pharma in select European markets. Cardiome has also licensed TREVYENT, a development state drug device combination that is under development for Pulmonary Arterial Hypertension, for Europe, the Middle East and for Canadian markets.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at [www.cardiome.com](http://www.cardiome.com).

---

19 December 2014

Cardiome Pharma Corp. (COM.TO) Enters Development And Commercialization Agreement With Eddingpharm For BRINAVESS In China

VANCOUVER, Dec 19, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that one of its subsidiaries has entered into an agreement with Eddingpharm to develop and commercialize BRINAVESS in China, Taiwan, and Macau and re-launch BRINAVESS in Hong Kong. Eddingpharm will be responsible for any clinical trials and regulatory approvals required to commercialize BRINAVESS in the countries covered by the agreement. Under the terms of the agreement, Eddingpharm has agreed to an upfront payment of US \$1.0 million and specific annual commercial goals for BRINAVESS. Cardiome is also eligible to receive regulatory milestone payments of up to US \$3.0 million. Other financial details have not been disclosed.

"Cardiome is extremely pleased to enter into this BRINAVESS development and commercialization agreement with Eddingpharm for China and these additional regions," said Karim Lalji, Cardiome's Chief Commercial Officer. "China is a market with significant opportunity and we have found a very competent partner in Eddingpharm who can unlock the full value of BRINAVESS in this rapidly growing region. Our agreement with Eddingpharm reaffirms Cardiome's dedication to have BRINAVESS available to all patients suffering from atrial fibrillation worldwide."

"Eddingpharm is excited to have the opportunity to develop and introduce BRINAVESS to the Chinese market," said Xin Ni, Eddingpharm's founder and CEO. "BRINAVESS will be a key hospital product for the future of our company and we are committed to making this drug available to all our customers throughout the regions covered by this agreement."

In 2012, the Chinese pharmaceutical market was estimated to be valued at US \$80B.<sup>1</sup>

#### References:

IMS Consulting Group. Growing Pains: China's new pharma realities, and the necessity of an informed strategy in bridging the gap between assumed and realized growth, 2013 About Cardiome Pharma Corp. Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at [www.cardiome.com](http://www.cardiome.com).

#### About Eddingpharm

Founded in 2001, Eddingpharm is a fast growing specialty pharmaceutical company in the Chinese market, committed to actively introducing quality products into China's pharmaceutical market. The Company focuses on the development and promotion of pharmaceutical products in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. Eddingpharm has established long-term cooperative relationships with a number of multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built up a competitive product portfolio and pipeline in the four major therapeutic areas. Eddingpharm recently established its U.S. affiliate and set up a product development team with R&D capabilities in Los Angeles, CA, USA, to coordinate and communicate with leading global R&D institutions and explore opportunities for introducing innovative pharmaceutical products in China. The Company currently employs over 700 people.

#### Filing Data

*Not available.*

#### Contract

*Not available.*